Development of a novel targeting therapy using anti-podoplanin antibody against malignant pleural mesothelioma

2015 Fiscal Year Final Research Report

• Project/Area Number: 25460189
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: The University of Tokushima
• Principal Investigator: ABE Shinji 徳島大学, 大学院医歯薬学研究部, 助教 (00403717)
• Co-Investigator(Kenkyū-buntansha): NISHIOKA Yasuhiko 徳島大学, 大学院医歯薬学研究部, 教授 (70274199)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: トランスレーショナルリサーチ / 抗体医薬 / ADCC / ポドプラニン / 個別医療 / 悪性胸膜中皮腫

Outline of Final Research Achievements

Malignant pleural mesothelioma (MPM) is mainly caused by exposure to asbestos, develops in the pleural cavity with a high likelihood of malignancy. Development of novel therapies for MPM is warranted in order to improve very poor prognosis. In this study, we investigated whether anti-human podoplanin antibodies can induce antitumor effects in MPM. Using podoplanin positive human MPM cell lines, anti-human podoplanin antibodies with NK cells induced significant antitumor effect. Our results strongly suggest that anti-human podoplanin antibodies might provide an efficacious therapeutic strategy for the treatment of MPM.

Free Research Field

臨床薬学